In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application

Human Mutation
R L Blakley, B P Sorrentino

Abstract

Mammalian cells cultured in the presence of the chemotherapeutic agent, methotrexate, develop resistance to this drug. Sometimes this is due to mutations in the gene for dihydrofolate reductase, the primary target of methotrexate. However, it has not been possible to link such polymorphism to resistance of neoplastic disease to therapy with methotrexate. Nevertheless, interest in this possibility lead to the introduction of many mutations into the cDNA for human DHFR by mutagenesis. Most of the corresponding enzyme variants have been expressed in Escherichia coli and characterized. Many mutations in codons for hydrophobic residues at the active site greatly decrease inhibition by methotrexate, and by the related substrate analogue, trimetrexate, while allowing the retention of considerable catalytic efficiency. Introduction of some of these mutants into mammalian cells by retroviral transfer provides substantial protection from toxic effects of the inhibitors, and has promise for the myeloprotection of patients receiving therapy with methotrexate or trimetrexate. Another potential use is in therapy for inherited disorders of hematopoiesis, where genetic modification of enough cells is a perennial problem. After transplantation ...Continue Reading

References

Sep 11, 1991·Nucleic Acids Research·M H PolymeropoulosC R Merril
May 17, 1988·Biochemistry·N J PrendergastJ H Freisheim
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·C C Simonsen, A D Levinson
Dec 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J H GoldieS Dedhar
Jan 1, 1993·Leukemia & Lymphoma·J R Bertino, E Göker
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A P DickerJ R Bertino
Oct 3, 1996·The New England Journal of Medicine·R GorlickJ R Bertino

❮ Previous
Next ❯

Citations

Mar 21, 2002·The Lancet Oncology·Debabrata Banerjee, Joseph R Bertino
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·N UchidaI L Weissman
Nov 30, 2007·Biochemical and Biophysical Research Communications·Ningwen TaiEdward Chu
Dec 6, 2005·European Journal of Pharmacology·Joslynn G AffleckVirginia K Walker
Feb 1, 2006·Expert Opinion on Therapeutic Patents·Giorgio V Scagliotti, Giovanni Selvaggi
Sep 18, 2007·Journal of Molecular Biology·Jordan P VolpatoJoelle N Pelletier
Aug 22, 2002·Nature Reviews. Cancer·Brian P Sorrentino
Jun 21, 2008·Journal of Biomolecular Screening·Elena FossatiJoelle N Pelletier
Jan 1, 2009·Clinical Medicine. Oncology·Anthony R VorthermsRobert P Doyle
Aug 22, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Junbiao WangAugusto Amici
Feb 11, 2005·Chemical Reviews·Ivan M KompisRudolf L Then

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.